An interactive map about institutional investors and their engagement in the stock market
Equity Distribution for GILEAD SCIENCES Inc
| Ticker | GILD |
| FIGI | BBG000CKGBP2 |
| CUSIP | 375558103 |
| Sector | Healthcare |
| Equity Type | Common Stock |
| No. Companies Holding this Equity | 1588 / 22.6% |
| Percentage held by institutional investors | 81.8% |
About
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500. Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Wikipedia